Targeting the Immunosuppressive Tumor Microenvironment through Combining the TVAX Vaccination & Adoptive Cell Therapy Platform with OV
Time: 10:00 am
day: Day Two
Details:
• How the TVAX immunotherapy platform employs multiple modalities, including vaccination and autologous adoptive T cell therapy to target recurrent glioblastoma
• How to address challenges in targeting the tumor microenvironment, demonstrated through clinical data from patients with newly diagnosed glioblastoma receiving the TVIBrain-1
• How to overcome tumor microenvironment immunosuppression through the combination of TVAX immunotherapy with oncolytic virotherapy
